Insulin glulisine

drugbox
IUPAC_name =

---

CAS_number = 207748-29-6
ATC_prefix = A10
ATC_suffix = AB06
PubChem =
DrugBank =
C=258|H=384|N=64|O=78|S=6
molecular_weight = 5823
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
excretion =
pregnancy_AU =
pregnancy_US = C
pregnancy_category=
legal_AU =
legal_CA =
legal_UK = POM
legal_US = Rx-only
legal_status =
routes_of_administration = Subcutaneous

Insulin glulisine is a rapid-acting insulin analogue that differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid. Chemically, it is 3B-lysine-29B-glutamic acid-human insulin, has the empirical formula C₂₅₈H₃₈₄N₆₄O₇₈S₆ and a molecular weight of 5823. It was developed by Sanofi-Aventis and sold under the trade name Apidra. When injected subcutaneously, it appears in the blood earlier and at higher concentrations that human insulin. When used as a meal time insulin, the dose should be given within 15 minutes before a meal or within 20 minutes after starting a meal.

External links

* [http://products.sanofi-aventis.us/apidra/apidra.html Apidra Homepage]
*http://www.genome.jp/dbget-bin/www_bget?dr:D04540